Form 4: Travere Therapeutics Executive William Rote Reports Stock Transactions

William E. Rote, Chief Research Officer at Travere Therapeutics, reports the vesting of performance-based restricted stock units and subsequent sale of shares.

Summary

• William E. Rote, Chief Research Officer of Travere Therapeutics, reported transactions involving the company's common stock.
• On May 2, 2025, 4,920 performance-based restricted stock units (PSUs) vested due to the achievement of a performance criterion related to cumulative FILSPARI net revenue.
• These PSUs represent a contingent right to receive one share of Travere Therapeutics common stock each.
• Following the vesting, Rote sold 3,198 shares of common stock on May 5, 2025, at a price of $21.05 per share.
• The sale was executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on March 15, 2024, and included shares to cover tax obligations arising from the PSU vesting.
• After these transactions, Rote directly owns 100,241 shares of Travere Therapeutics common stock and 4,920 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, reporting routine stock transactions. The vesting of PSUs is a positive signal, but the subsequent sale is a slightly negative one, resulting in a moderately positive sentiment.

Positives

• The vesting of PSUs indicates that Travere Therapeutics achieved a performance criterion related to cumulative FILSPARI net revenue, which could be viewed positively.

Negatives

• The sale of shares by a company executive could be interpreted negatively by some investors, although it was conducted under a pre-arranged trading plan.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create short-term price volatility.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of PSUs suggests confidence in the company's performance related to FILSPARI net revenue.

Industry Context

Executive stock transactions are common and are often scrutinized by investors for insights into management's perspective on the company's prospects. Rule 10b5-1 plans are frequently used to mitigate concerns about insider trading.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity awards like PSUs to align management's interests with those of shareholders.
• The vesting of PSUs based on revenue targets is a common practice in the pharmaceutical industry, where product sales are a key performance indicator.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use similar performance-based equity compensation structures.

Stakeholder Impact

• The vesting of PSUs and subsequent stock sale may have a minor impact on shareholder sentiment.

Key Dates

Keywords

Travere Therapeutics, William Rote, stock sale, Form 4, PSU, FILSPARI, Rule 10b5-1, executive compensation, insider trading